Please login to the form below

Not currently logged in
Email:
Password:

peglispro

This page shows the latest peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a potential toxicity issue made the project

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Discontinues development of medicine once tipped as a diabetes blockbuster.  . Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for type 1 and ... Analysts have been divided on the

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed filings for its long-acting insulin peglispro candidate after a safety signal was seen in

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The company also released the results of five phase III studies of its long-acting insulin peglispro, which had a serious setback earlier this year when liver fat changes seen in ... However, some of the IMAGINE trials showed an increase in the liver

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety concerns.

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    Until recently, additional competition was also looming in the form of Lilly's long-acting insulin peglispro, although that project has now been significantly delayed after fatty liver changes were seen

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics